Second-Line Angiogenesis Inhibition for mRCC
In this segment, panelists discuss the utilization of second-line angiogenesis inhibitors, such as axitinib and bevacizumab, for the treatment of patients with metastatic renal cell carcinoma.
In this segment, panelists discuss the utilization of second-line angiogenesis inhibitors, such as axitinib and bevacizumab, for the treatment of patients with metastatic renal cell carcinoma.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Researchers identified 15 genes that they said independently predict the survival outcome of patients with kidney renal papillary cell carcinoma.
Evidence suggests that starting on systemic drug therapy immediately may be the best approach for some patients with metastatic RCC.
Significantly fewer patients had radical nephrectomy in 2004 compared with 2015.